{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:36:14Z","timestamp":1777509374854,"version":"3.51.4"},"reference-count":48,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Venous thromboembolism (VTE) may jeopardise excellent treatment results of germ cell tumours (GCT). We previously constructed a VTE risk score for GCT patients qualified for first\u2010line chemotherapy (CTH), including vein compression, clinical stage (CS) and haemoglobin concentration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Validating our score in a separate cohort and establishing the cut\u2010off point for the score. Re\u2010assessing the numerical score in the training cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>We retrospectively analysed a new cohort of GCT patients staged IS\u2013IIIC. Area under the curve of receiver\u2010operating characteristic (AUC\u2010ROC) was calculated for the developed score, Khorana Risk Score (KRS) and Padua Prediction Score (PPS). AUC\u2010ROC of the integer score was calculated for the training cohort. Cut\u2010off point was established by Youden's and Liu's indices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 336 eligible patients in the validation cohort, VTE occurred in 41 (12.2%). AUC\u2010ROC for our score, KRS and PPS were 0.818 (95% confidence interval (CI): 0.746\u20130.891), 0.608 (0.529\u20130.688) and 0.634 (0.547\u20130.720), respectively, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001. The optimal cut\u2010off point for a low\/high risk was 6 (\u2264\u20096 vs. \u2265\u20097). In the training cohort, 369 patients had complete data on vein compression. AUC\u2010ROC for our score, KRS and PPS were 0.819 (95% CI: 0.758\u20130.879), 0.710 (0.637\u20130.782) and 0.725 (0.651\u20130.800), <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.001 and 0.015, respectively. Positive and negative predictive values were 30.8% and 96.5%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our VTE risk score is a handy tool for GCT patients before first\u2010line CTH for metastatic disease. Outperforming KRS and PPS, it has a good discriminatory value, especially for identifying low\u2010risk patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70295","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:45:02Z","timestamp":1728571502000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simple, Effective and Validated. VTE CASE Risk Assessment Score for Venous Thromboembolism in Metastatic Germ Cell Tumour Patients Before First\u2010Line Chemotherapy"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7746-0839","authenticated-orcid":false,"given":"Wojciech","family":"Michalski","sequence":"first","affiliation":[{"name":"Department of Urological Cancer Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5441","authenticated-orcid":false,"given":"Anna","family":"Macios","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"Poniatowska","sequence":"additional","affiliation":[{"name":"Department of Urological Cancer Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Zastawna","sequence":"additional","affiliation":[{"name":"Centre of Clinical Cardiology and Rare Cardiovascular Diseases National Medical Institute of the Ministry of the Interior and Administration  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Demkow","sequence":"additional","affiliation":[{"name":"Department of Urological Cancer Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Wiechno","sequence":"additional","affiliation":[{"name":"Department of Urological Cancer Maria Sk\u0142odowska\u2010Curie National Research Institute of Oncology  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000355652"},{"key":"e_1_2_12_3_1","first-page":"1","article-title":"Large Retroperitoneal Lymphadenopathy and Increased Risk of Venous Thromboembolism in Patients Receiving First\u2010Line Chemotherapy for Metastatic Germ Cell Tumors: A Study by the Global Germ Cell Cancer Group (G3)","volume":"9","author":"Tran B.","year":"2019","journal-title":"Cancer Medicine"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.6537"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000471888"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2021.07.007"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01180"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.002"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4358"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2598-7"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw265"},{"key":"e_1_2_12_13_1","unstructured":"NCCN Guidelines Version 2.2023 \u201cCancer\u2010Associated Venous Thromboembolic Disease \u201daccessed March 25 2024 www.nccn.org."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6458"},{"key":"e_1_2_12_15_1","first-page":"195","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley J. D.","year":"2017"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec173d"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.03.031"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S320492"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231186790"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-22-0112"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.62347\/LNDL8700"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01259-7"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.988287"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24466"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00534-y"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007699"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06511-3"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01542"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0414"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.09.001"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i3.183"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176283"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512055"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2022.10.005"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211024756"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602791"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.10.003"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(16)60026-X"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.09.017"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.03.013"},{"issue":"2","key":"e_1_2_12_41_1","first-page":"94","article-title":"Chemotherapy\u2010Induced Hypercoagulability and Biomarkers for Prediction of Thromboembolic Events in Patients With Metastatic Testicular Cancer","volume":"11","author":"Lubberts S.","year":"2013","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz177"},{"issue":"6","key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1213\/ANE.0000000000005362","article-title":"Developing a Clinical Prediction Score: Comparing Prediction Accuracy of Integer Scores to Statistical Regression Models","volume":"132","author":"Subramanian V.","year":"2021","journal-title":"Anesthesia & Analgesia"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000445126"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081937"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1735251"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002273"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2019.12.004"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14774"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T16:48:10Z","timestamp":1747673290000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":48,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1002\/cam4.70295"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70295","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70295"}}